Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
Adaptive Biotechnologies reported Q1 2026 revenue of $70.9 million, a 35% year-over-year increase, driven primarily by a 53% jump in MRD revenue to $67.1 million. clonoSEQ test volume rose 41% to 32,595 tests, and the company recognized a $9.0 million regulatory milestone, its first U.S. primary endpoint milestone.
Key figures
- Revenue
- 70900000
- Guidance
- FY2026 MRD revenue $260M-$270M, raised from $255M-$265M
- Revenue Yoy
- 35%
- Mrd revenue
- 67100000
- Mrd revenue yoy
- 53%
- Clonoseq volume yoy
- 41%
- Clonoseq tests volume
- 32595
- Cash marketable securities
- 237200000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.